ER-positive and BRCA2-mutated breast cancer: a literature review

Abstract

Abstract BRCA2-mutated carriers have a high lifetime risk of breast cancer (BC), an early age of onset, and an increased risk of other cancers (including ovarian, pancreatic, and prostate cancer). Almost 70–80% of BRCA2-mutated BC are estrogen receptor (ER)-positive, which is a particular type of ER-positive BC that differs from sporadic ER-positive BC. This article reviews the clinicopathological features, treatment, and prognosis of ER-positive and BRCA2-mutated BC to provide a reference for clinical decision-making.

Keywords

• Breast cancer
• BRCA2 mutation
• ER-positive
• PARP inhibitor
• CDK4/6 inhibitor
• Survival rate